It covers a method of treating insomnia by administering zolpidem to humans utilising NovaMist oral spray.
NovaDel’s Zolpimist (zolpidem tartrate) 5 mg and 10 mg oral spray product is approved by the FDA for the short-term treatment of insomnia characterised by difficulties with sleep initiation.
Zolpimist is NovaDel’s second product approved by the FDA that uses its proprietary NovaMist oral spray technology.
Reportedly, NovaDel maintains a portfolio of intellectual property rights for select compounds using its oral spray delivery system.
Upon issuance of the application, the company will have been granted nine patents in the US, three patents in Canada and 66 patents throughout Europe. This patent will expire in 2018.